Status: Not yet recruiting
A Phase 1 Study of VELA-101 in Adult Participants
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses via subcutaneous (SC) administration.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Ursa MedicinesUpdated: Oct 7, 2026Locations: 2
Eligibility criteria
Participants must be adults able to understand the study, provide written inform... [+4]
Known familial hypercholesterolemia or severe hypertriglyceridemia. [+6]